Clinical trial · Observational
Computational Prediction and Experimental Validation of Esophageal Cancer Associated Neoantigens
NCT05498168CI-TRIAL-00060271unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is to develop computational pipelines and experimental validation assays for improving the identification of neoantigens from patients with esophageal cancer.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Esophageal Cancer | Malignant Esophageal Neoplasm | CURATED_EXACT | 0.92 |
| Neoantigen | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ratio of predicted neoantigens | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (3)
- measure
- The neoantigen landscape of patients with esophageal cancer
- timeFrame
- 3 months from the begining of study
- description
- The analysis of tumor DNA and RNA sequencing data will provide the mutational distribution of patients with esophageal cancer, which could give rise to neoantigens. Of those, neoantigens derived from hotspot mutations in Vietnamese esophageal cancer patients will be identified.
- measure
- The ratio of predicted neoantigens being presented by HLA-I
- timeFrame
- 6 months from the begining of study
- description
- Computational pipelines will be employed to predict the pairing of neoantigens and HLA molecules. Subsequently, the ratio of those predicted neoantigens will be validated by co-immunoprecipitation with anti-HLA antibodies and mass spectrometry analysis for their binding to corresponding HLA molecules.
- measure
- The ratio of predicted neoantigens being immunogenic
- timeFrame
- 12 months from the begining of study
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 15 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: 1. Male or Female patients aged 18 years and older 2. Diagnosed with advanced esophageal cancer 3. Treatment-Naive 4. Not known for other concomitant cancers 5. Provide written informed consent Exclusion Criteria: 1. Insufficient tumor tissues (less than 1 cm3 ) 2. Unable to sign informed consent 3. Underwent treatment
References
Publications (0)
Data not yet available
No reference posted for this study.